Ventyx Biosciences shares are trading lower after the company announced efficacy results from the Phase 2 trial of VTX958 in plaque psoriasis did not meet the internal target to support further development of VTX958 in psoriasis.
Portfolio Pulse from Benzinga Newsdesk
Ventyx Biosciences announced that the Phase 2 trial of VTX958 in plaque psoriasis did not meet the internal target, which does not support further development of VTX958 in psoriasis. This has led to a decrease in the company's share price.
November 06, 2023 | 9:58 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Ventyx Biosciences' shares are trading lower after the company announced disappointing results from the Phase 2 trial of VTX958 in plaque psoriasis.
The company's shares are trading lower due to the disappointing results from the Phase 2 trial of VTX958 in plaque psoriasis. This indicates a lack of progress in the company's product development, which is a negative signal to investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100